C. difficile across Canada in the past few years, most recently in Ottawa and St. Catharines, Ont.
Although C. difficile can also be acquired in the community, it is most frequently acquired at hospitals and long-term care facilities.
The Br J Clin Pharmacol study advises physicians to avoid prescribing diclofenac to those who are at risk for C. difficile. Study author Dr. Paul Brassard, assistant professor in the Department of Medicine at McGill University Health Centre, Montréal, Que. says the study began as a result of case reports linking diclofenac and C. difficile. Brassard says they found a "small increase in risk."
Brassard did not see this increase in risk as a reason to immediately delist the medication. "One has to look at the risk-benefit of using this medication, and see what the best usage of the medication would be," he says.
"You don't expect just one study to change practice," said Brassard. "The findings have to be consistent and reproducible over time so it finally gets into the field and eventually changes the practice. And that always takes a number of years." -Sarah Spitz, CMAJ
